We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $522M
1-Year Est. Return 281.95%
This Fund
S&P 500
This Quarter Est. Return
-9.68%
1 Year Est. Return
+281.95%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$340M
AUM Growth
-$38.1M
Cap. Flow
+$16M
Cap. Flow %
4.71%
Top 10 Hldgs %
55.38%
Holding
79
New
17
Increased
14
Reduced
10
Closed
36

Top Buys

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$17.3M
2
IMVT icon
Immunovant
IMVT
+$10.9M
3
MRK icon
Merck
MRK
+$10.5M
4
GSK icon
GSK
GSK
+$10.3M
5
ACLX
Arcellx
ACLX
+$7.63M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$11.7M
2
ARQT icon
Arcutis Biotherapeutics
ARQT
+$11.2M
3
ROIV icon
Roivant Sciences
ROIV
+$9.22M
4
TARS icon
Tarsus Pharmaceuticals
TARS
+$8.08M
5
INSM icon
Insmed
INSM
+$7.19M

Sector Composition

Rank Sector Weight
1 Healthcare 99.45%
2 Financials 0.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNDX icon
1
Syndax Pharmaceuticals
SNDX
$2.02B
$29M 8.52%
1,412,176
+311,188
+28% +$6.51M
ROIV icon
2
Roivant Sciences
ROIV
$24.8B
$28.7M 8.43%
2,712,741
-841,103
-24% -$9.22M
IMVT icon
3
Immunovant
IMVT
$8.27B
$26.7M 7.85%
1,011,879
+384,651
+61% +$10.9M
CRNX icon
4
Crinetics Pharmaceuticals
CRNX
$8.88B
$24.7M 7.25%
551,095
-68,694
-11% -$3.17M
MRUS
5
DELISTED
Merus
MRUS
$17.1M 5.02%
288,668
+54,797
+23% +$2.65M
ACLX
6
DELISTED
Arcellx
ACLX
$15.5M 4.55%
280,709
+140,442
+100% +$7.63M
FOLD
7
DELISTED
Amicus Therapeutics
FOLD
$14.8M 4.36%
1,495,047
-52,094
-3% -$535K
IMCR icon
8
Immunocore
IMCR
$1.78B
$11.5M 3.38%
+339,351
New +$17.3M
APLT
9
DELISTED
Applied Therapeutics
APLT
$10.3M 3.03%
2,211,320
+194,304
+10% +$919K
MRK icon
10
Merck
MRK
$315B
$10.2M 2.98%
+81,508
New +$10.5M
GSK icon
11
GSK
GSK
$104B
$9.47M 2.78%
+245,933
New +$10.3M
AUTL
12
Autolus Therapeutics
AUTL
$383M
$9.27M 2.72%
2,662,732
-302,989
-10% -$1.31M
ARQT icon
13
Arcutis Biotherapeutics
ARQT
$3.56B
$8.98M 2.64%
965,392
-1,240,507
-56% -$11.2M
CABA icon
14
Cabaletta Bio
CABA
$461M
$8.81M 2.59%
1,178,105
+174,189
+17% +$2.14M
KALV
15
DELISTED
KalVista Pharmaceuticals
KALV
$8.68M 2.55%
736,765
-424,295
-37% -$4.95M
BHVN icon
16
Biohaven
BHVN
$2.32B
$8.1M 2.38%
233,255
+149,794
+179% +$5.92M
VTGN icon
17
VistaGen Therapeutics
VTGN
$9.4M
$5.85M 1.72%
1,848,582
– –
IMTX icon
18
Immatics
IMTX
$1.31B
$5.84M 1.72%
502,207
+10,281
+2% +$116K
DNLI icon
19
Denali Therapeutics
DNLI
$3.7B
$5.83M 1.71%
+251,010
New +$4.82M
INSM icon
20
Insmed
INSM
$23.5B
$5.83M 1.71%
86,980
-185,468
-68% -$7.19M
CLDX icon
21
Celldex Therapeutics
CLDX
$2.77B
$5.35M 1.57%
+144,467
New +$5.45M
LRMR icon
22
Larimar Therapeutics
LRMR
$384M
$5.11M 1.5%
704,349
-36,528
-5% -$280K
TCRX icon
23
TScan Therapeutics
TCRX
$59.8M
$4.94M 1.45%
+845,069
New +$6.66M
EWTX icon
24
Edgewise Therapeutics
EWTX
$4.28B
$4.88M 1.43%
+271,057
New +$4.73M
CRBP icon
25
Corbus Pharmaceuticals
CRBP
$167M
$4.59M 1.35%
+101,479
New +$4.27M
1
2 3 4

Similar funds

JE
JMAC Enterprises Newtown, Pennsylvania $522M AUM 15.34% 1-Year Est. Return
GS
GWN Securities Palm Beach Gardens, Florida $523M AUM 20.1% 1-Year Est. Return
LT
Legacy Trust Grand Rapids, Michigan $522M AUM 23.56% 1-Year Est. Return
WFA
WestHill Financial Advisors San Rafael, California $523M AUM 15.95% 1-Year Est. Return
TCM
TruNorth Capital Management Kalamazoo, Michigan $522M AUM 14.26% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
ETS
ESL Trust Services Rochester, New York $524M AUM 17.18% 1-Year Est. Return
CM
Conifer Management New York $524M AUM 14.11% 1-Year Est. Return

Stempoint Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Stempoint Capital held 79 positions worth $340M, down 10% from $378M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Stempoint Capital deployed $16M of net new capital in Q2 2024, opening 17 new positions and adding to 14 existing holdings. Its largest new stake was Immunocore: 339,351 shares worth $11.5M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Arcutis Biotherapeutics, an estimated $11.2M trimmed.

  • Stempoint Capital's largest Q2 2024 buy was Immunocore: 339,351 shares worth $11.5M.
  • Stempoint Capital added most to Immunovant in Q2 2024, an estimated $10.9M increase.
  • Stempoint Capital's biggest Q2 2024 reduction was Arcutis Biotherapeutics, cutting an estimated $11.2M.
  • Stempoint Capital fully exited Eli Lilly in Q2 2024, selling an estimated $11.7M.
  • Stempoint Capital's ten largest holdings make up 55% of its $340M portfolio in Q2 2024.
  • Stempoint Capital opened 17 new positions and closed 36 in Q2 2024.
  • Stempoint Capital's portfolio value fell 10% quarter-over-quarter to $340M.

Based on Stempoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.